- Primary research
- Open Access
Anticonvulsant and analgesic activities of crude extract and its fractions of the defensive secretion from the Mediterranean sponge, Spongia officinalis
© Dellai; licensee BioMed Central Ltd. 2012
- Received: 1 March 2012
- Accepted: 11 April 2012
- Published: 11 April 2012
This study progresses in the direction of identifying component(s) from the Mediterranean sponge, Spongia officinalis with anticonvulsant and analgesic activities. We investigated the efficacy of crude extract and its semi-purified fractions (F1-F3) of the defensive secretion from Spongia officinalis for their in vivo anticonvulsant activity using the pentylenetetrazole (PTZ) seizure model and analgesic activity using the writhing test in mice. Among the series the crude extract exhibited interesting analgesic activity in a dose dependent manner. Similarly the fraction F2 showed a partial protection of mice from PTZ-induced seizure and interesting analgesic activity in a dose dependent manner. The purification and the determination of chemical structure(s) of compound(s) of this active fraction are under investigation.
- Spongia officinalis
- Anticonvulsant activity
- Analgesic activity
The inability to cure contemporary disease such as cancer, AIDS, arthritis, Alzheimer and the growing incidence of drug-resistant infection diseases have stimulated the need for the development of new drugs from natural sources. Since the few last decades, marine environment have been recognized to be a rich sources of bioactive metabolites with varied biological and pharmacological activities [1, 2]. Covering around 70% of the planet surface, the oceans possess a huge potential for the new discovery often on novel molecules. The most interesting phyla with respect to pharmacologically active marine compounds include bacteria, fungi, algae, soft corals and gorgonians, sea hares and nudibranchs, bryozoans, tunicates and especially sponges . Marine sponges have been considered as a gold mine during the past few decades with respect to the diversity of their secondary metabolites and continue to provide novel natural products with a remarkable chemical diversity. It is not surprising that a sponge natural product possessed different pharmacological properties such as ceramide from Negombata corticata which displayed anticonvulsant activitiy; manoalide, a sesterpenoid compound, from Luffariella variabilis which displayed anti-inflammatory, analgesic and antibacterial activities [5, 6]. The objective of the present study was to evaluate for the first time the potency of crude extract and its semi-purified fractions (F1-F3) of the defensive secretion from Spongia officinalis for inhibiting convulsion induced by PTZ and for inhibiting writhes induced by acetic acid and phenylbenzoquinone with the aim of identifying novel molecules with interesting and potentially useful pharmacological activities.
Sample collection and preparation of the extract
The marine sponge, Spongia officinalis was collected from the Mediterranean Sea, in various areas of the coastal region of Tunisia, at a depth between 2 and 3 meters. The collected samples were cleaned by rising with sea water and distilled water and transported in cool box to the laboratory where they are kept in a refrigerator in distilled water for 24 h. Identification of specimen was carried out in the National Institute of Marine Sciences and Technologies, Salamboo, Tunisia.
The samples were defrosted before use and then filtered using some cotton wool followed by passage through a Whatman filter paper # 1. The filtrate was lyophilized to give the crude extract of the defensive secretion. The powdered extract was stored at −20°C until use.
Purification of the crude extract of the defensive secretion
Often, bioactive compounds constitute a very minor part of the crude extract. In order to localize the active fraction, extract of the defensive secretion of Spongia officinalis was purified, using C18 cartridges (Sep-pack, Supelco), by gradient elution with methanol–water mixture (0%, 25%, 50% and 80% methanol) to give 4 fractions (F0-F3). Methanol solvent was removed from fractions recuperated using rotating evaporator at 35°C and distilled water was then added to the residues and the aqueous phases were lyophilized. The powdered fractions were stored at −20°C until use.
Crude extract and fractions were diluted to the desired final concentration immediately prior manipulation.
Swiss mice (20–30 g) of both sexes, provided from Pasteur institute (Tunis, Tunisia) were used. Animals were fed a standard diet ad libitum and allowed free access to drinking water. Housing conditions and in vivo experiments were approved according to the guidelines established by the European Union on Animal care (CEE Council 86/609).
Anticonvulsant study in mice
Anticonvulsant activity was assessed according to the method described by Vogel . Swiss mice of either sex (20–30 g) were used. Animals were divided into three groups of six mice each. Group one served as control and was treated with 10 ml/kg of saline by subcutaneous injection (s/c), the second group was given phenobarbital (120 mg/kg) (s/c) as a reference drug, and the third group was treated with the crude extract of the defensive secretion from Spongia officinalis (100, 200 and 400 mg/kg) and its semi purified fractions (F1-F3) at 200 mg/kg (s/c), 30 min before the intraperitoneal (i.p.) injection of pentylenetetrazole (PTZ) (90 mg/ml). The time taken before the onset of clonic convulsions, the duration of clonic convulsions, and the percentage of seizure and mortality protection were recorded. These parameters were compared in treated animals with those of control animals, in order to assess the anticonvulsant activity.
Acetic acid writhing test in mice
The analgesic activity was performed according to the method of Koster et al. . Swiss mice (20–30 g) were selected one day prior to each test and were divided into three groups of six mice each. One group served as control (saline 10 ml/kg) (s/c). The second group was given the lysine acetylsalicylate (ASL) (200 mg/kg) by the same route, as a reference drug. The remaining group was treated with the crude extract of the defensive secretion from Spongia officinalis (100, 200 and 400 mg/kg) and its semi purified fractions F1, F3 at 200 mg/kg and F2 (50, 100 and 200 mg/kg) (s/c). All animals received 10 ml/kg (i.p.) of 1% acetic acid 30 min after treatment. The number of writhing was recorded during 30 min commencing 5 min after the acetic acid injection. A writhe is indicated by abdominal constriction and stretching of at least one hind limb.
Phenylbenzoquinone (PBQ) writhing test in mice
Swiss mice (20–30 g) were used. In this test the same procedure was used as described above, but writhing was induced by i.p. injection of 10 ml/kg of 0.04% PBQ in a 5% ethanol aqueous solution . Antinociceptive activity was detected as a reduction in the number of abdominal constrictions exhibited by treated mice, with standard drug or with the sponge extract and its semi-purified fractions, as compared to the nociception control group, and was expressed as the percent of pain inhibition.
Acute toxicity study
Eighty mice were divided into eight groups of ten animals each. One group served as a control and received 0.9% NaCl alone (10 ml/kg) given intraperitoneally, while the remaining seven groups were treated with increasing doses of the crude extract of the defensive secretion from Spongia officinalis; 300, 500, 700, 800 and 1000 mg/kg (i.p.), respectively. The mortality rate within a 24 h period was determined and the LD50 was estimated according to the method described by Miller and Trainter . According to the results of acute toxicity test, the doses of 100, 200 and 400 mg/kg were chosen for experiments.
Data are presented as the mean ± standard error (s.e.m). Statistical analysis was performed using Student’s t-test. The significance of difference was considered to include values of P < 0.05.
Anticonvulsant effect of the subcutaneous administration of crude extract and its semi-purified fractions (F1-F3) of the defensive secretion of Spongia officinalis in the PTZ model in mice
Onset of first clonus (s)
Seizure protection (%)
Mortality protection (%)
(saline 10 ml/kg)
180.16 ± 53.66
15 ± 1.16
149 ± 35.77ns
12 ± 87.24ns
251 ± 17.88 ns
10.7 ± 3.57ns
600 ± 0**
5 ± 2.68**
251 ± 9.83*
18 ± 3.57ns
247 ± 17.88 ns
8.7 ± 1.97**
800 ± 17.88**
4 ± 0.71**
1200 ± 89.44**
1 ± 0.89**
249 ± 10.73 ns
13 ± 1.07ns
Phenobarbital (reference drug)
Most antiepileptic drugs are known to have strong analgesic effects . Moreover the available analgesic drugs exert a wide range of side effects and are either too potent or too weak; the search for new analgesic compounds has been a priority of pharmacologists and pharmaceutical industries .
Analgesic effect of the subcutaneous administration of crude extract and its semi-purified fractions (F1-F3) of the defensive secretion of Spongia officinalis in the acetic acid 1% writhing test in mice
Number of writhes
inhibition of writhing (%)
Control (saline 10 ml/kg)
82.33 ± 12.45
41.83 ± 12.52**
39 ± 5.76**
31 ± 3.46**
34 ± 3.79**
24 ± 2.09**
18.5 ± 5.43**
12 ± 4**
37 ± 3.88**
Lysine Acetylsalicylate (reference drug)
26.16 ± 8.37**
Analgesic effect of the subcutaneous administration of crude extract and its semi-purified fractions (F1-F3) of the defensive secretion of Spongia officinalis in the PBQ writhing test in mice
Number of writhes
inhibition of writhing (%)
Control (saline 10 ml/kg)
39 ± 2.6
14.33 ± 5.16**
12.33 ± 4.8**
9.66 ± 5.08**
12 ± 3.74**
11 ± 4.19**
8 ± 3.4**
7 ± 2.36**
11.33 ± 4.32**
Acetylsalicylate of lysine (reference drug)
10 ± 2.6**
Evaluating anticonvulsant and analgesic properties in a single assay may not provide a full understanding of the actions of fraction or its utility. Further work to establish the active chemical constituent(s) of the active fraction F2 and ascertain its mechanism of action is currently going on in our laboratory.
Some known anticonvulsant and analgesic agents, such as ceramide , manoalide , disideine  and avarol  have already been isolated from other sponges. However, marine sponges often contain diverse and abundant microbial communities, including bacteria which are the most dominant group of microbial association in sponges, archaea, microalgae and fungi. In some cases, these microbial associates comprise as much as 40% of the sponge volume and can contribute significantly to host metabolism [28, 29]. These data allows us to suggest that, in our case, the exact origin of the anticonvulsant and the analgesic properties remains unknown or from the active fraction of Spongia officinalis or from the symbiotic microorganisms. Isolation and cultivation of suspected symbiotic bacteria either from the surrounding sea-water or from the sponge could provide a better answer.
The authors acknowledge the “Ministry of Higher Education, Scientific Research and Technology, Tunisia”.
- Nishiguchi GA, Graham J, Bouraoui A, Jacobs RS, Daniel-Little R: 7,11-epi-Thyrsiferol: completion of its synthesis, evaluation of its antimitotic properties, and the further development of an SAR model. J Org Chem. 2006, 71: 5936-5941. 10.1021/jo060519z.View ArticlePubMedGoogle Scholar
- Ismail H, Lemriss S, Ben-Aoun Z, Mhadhebi L, Dellai A, Kacem Y, Boiron P, Bouraoui A: Antifungal activity of aqueous and methanolic extracts from the Mediterranean Sea Cucumber, Holoturia polii. J Med Mycol. 2008, 18: 23-26.View ArticleGoogle Scholar
- Monks NR, Lerrer C, Henriques AT, Farias FM, Schapoval EES, Suyenaga ES, Rocha ABD, Shwartsmann G, Mothes B: Anticancer, antichemotactic and antimicrobial activities of marine sponges collected off the coast of Santa Catrina, Southern Brazil. J Exp Mar Biol Ecol. 2002, 281: 1-12. 10.1016/S0022-0981(02)00380-5.View ArticleGoogle Scholar
- Ahmed SA, Khalifa SI, Hamann MT: Antiepileptic ceramides from the read sponge Negombata corticata. J Nat Prod. 2008, 71: 513-515. 10.1021/np0703287.View ArticlePubMedGoogle Scholar
- Mayer AMS, Jacobs RS: Manoalide: an anti-inflammatory and analgesic marine natural product. Memoirs Calif Acad Sc. 1988, 13: 133-Google Scholar
- De Silva ED, Scheur PJ: Manoalide, an antibiotic sesterterpenoid from the marine sponge Luffariella variabilis. Tetrahedron Lett. 1980, 21: 1611-1614. 10.1016/S0040-4039(00)77766-5.View ArticleGoogle Scholar
- Vogel HG, Vogel WH: Drug discovery and evaluation, pharmacological assay. Berlin Springer. 1997, 1997: 260-261.Google Scholar
- Koster R, Anderson M, DeBeer EJ: Acetic acid for analgesic screening. Fed Proc. 1959, 18: 418-420.Google Scholar
- Siegmund EA, Cadmus RA, Lu G: A method for evaluating both nonnarcotic and narcotic analgesics. Proc Soc Exp Biol. 1957, 95: 729-731.View ArticlePubMedGoogle Scholar
- Miller LC, Tainter ML: Estimation of EC50 and its error by means of log-probit graph paper. Proc Soc Exp Biol Med. 1944, 57: 261-264.View ArticleGoogle Scholar
- Nilsen KE, Kelso ARC, Cock HR: Antiepileptic effect of gap-junction blockers in a rat madel of refractory focal cortical epilepsy. Epilepsia. 2006, 47: 1169-1175. 10.1111/j.1528-1167.2006.00540.x.View ArticlePubMedGoogle Scholar
- Valentina B, Victor N, Galina V, Anatoly V: The influence of anticonvulsant and antioxidant drugs on nitric oxide level and lipid peroxidation in the rat brain during penthylentetrazole-induced epileptiform model seizures. Prog Neuro-Psychopharmacol Biol Psych. 2003, 27: 487-492. 10.1016/S0278-5846(03)00037-X.View ArticleGoogle Scholar
- Luisa R: Subchronic treatment with antiepileptic drugs modifies pentylenetetrazol-induced seizures in mice: its correlation with benzodiazepine receptor binding. Neuropsych Dis Treat. 2008, 4: 619-625.Google Scholar
- Radhakrishnan R, Zakaria MNM, Islam MW, Ismail A, Habibullat M, Chan K: Neuropharmacological actions of Portulaca oleracea v. sativa. J Pharm Pharmacol. 1998, 50: 225-View ArticleGoogle Scholar
- Ya’u J, Yaro AH, Abubakar MS, Anuka JA, Hussaini IM: Anticonvulsant activity of Carissa edulis (Vahl) (Apocynaceae) root bark extract. J Ethnopharmacol. 2008, 120: 255-258. 10.1016/j.jep.2008.08.029.View ArticlePubMedGoogle Scholar
- Mesdjian E, De Feudis FV, Valli M, Jadot G, Mandel P: Antinociceptive action of sodium valproate in the mouse. Gen Pharmac. 1983, 6: 697-699.View ArticleGoogle Scholar
- Mattison N, Trimple AG, Lasagna I: New drug development in the United States, 1963 through 1984. Clin Pharmacol Ther. 1998, 43: 290-301.View ArticleGoogle Scholar
- Mohammad A, Hoornaz K, Hamid RME: Antinociceptive effects of Teucrium polium L. total extract and essential oil in mouse writhing test. Pharmacol Res. 2003, 48: 31-35.Google Scholar
- Durate IDG, Nakamura M, Ferreira SH: Participation of the sympathetic system in acetic acid induced writhing in mice. Braz J Med Biol Res. 1988, 21: 341-343.Google Scholar
- Collier HOJ, Dineen LC, Johnson CA, Schneider C: Abdominal constriction response and its suppression by analgesic drugs in the mouse. B J Pharmacol Chemother. 1968, 32: 295-310.View ArticleGoogle Scholar
- Hendershot LC, Forsaith J: Antagonism of the frequency of phenylbenzoquinone induced writhing in the mouse by weak analgesics and nonanalgesics. J Pharmacol Exp Ther. 1959, 125: 237-240.PubMedGoogle Scholar
- Hunskaar S, Hole K: The formalin test in mice: dissociation between inflammatory and non-inflammatory pain. Pain. 1987, 30: 103-114. 10.1016/0304-3959(87)90088-1.View ArticlePubMedGoogle Scholar
- Dionne RA, Khan AA, Gordon SM: Analgesia and COX-2 inhibition. Clin Exp Rheumatol. 2001, 19: 63-70.Google Scholar
- Afef D, Audrey LC, Lamia M, Jacque R, Abderrahman B: Anti-inflammatory and antiproliferative acctivities of crude extract and its fractions of the defensive secretion from the mediterranean sponge, Spongia officinalis. D D R. 2010, 71: 412-418.View ArticleGoogle Scholar
- Jacobs RS, Culver P, Langdon R, O’Brien T, White S: Some pharmacological observations on marine natural products. Tetrahedron. 1985, 41: 981-984. 10.1016/S0040-4020(01)96465-8.View ArticleGoogle Scholar
- De Pasquale R, Circosta C, Occhiuto F, de Rosa S, de Stefano S: Central nervous system activity of terpenoids from marine sponge. Pharmacol Res Commun. 1988, 5: 23-26.View ArticleGoogle Scholar
- De Pasquale R, Circosta C, Occhiuto F, de Rosa S, de Stefano S: Pharmacological studies on terpenoids from marine sponges: analgesic and muscle relaxant effects. Phytother Res. 1991, 5: 49-53. 10.1002/ptr.2650050202.View ArticleGoogle Scholar
- Michael WT, Regina R, Doris S, Michael W: Sponge-associated microorganisms: evolution, ecology and biotechnological potential. Microbiol Mol Biol Reviews. 2007, 71: 295-347. 10.1128/MMBR.00040-06.View ArticleGoogle Scholar
- Onon L, Yue HW, Pei-Yuan Q: Inter and intraspecific variations of bacterial communities Associated with marine sponges from San Juan Island, Wash. App Env Microbiol. 2009, 75: 3513-3521. 10.1128/AEM.00002-09.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.